
    
      Patients of acute myeloid leukemia after chemotherapy with MRD(minimal residual disease) will
      receive NK cell infusion combined with consolidation chemotherapy. The bone marrow morphology
      and MRD remission of the patients will be observed 15 days after the same treatment. All
      patients will be followed up for 1 year.

      NK cells are prepared in Beijing iCELL Biotechnology Co.,Ltd, which is subsidiary to Shanghai
      iCELL Biotechnology Co.,Ltd.
    
  